Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug
AI Sentiment
Highly Positive
8/10
as of 12-10-2025 4:00pm EST
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | CHESIRE |
| Market Cap: | 598.7M | IPO Year: | 2020 |
| Target Price: | $16.43 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $7.08 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CMPS Breaking Stock News: Dive into CMPS Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how CMPS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CMPS COMPASS Pathways Plc American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.